S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination

ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News

$24.78
+0.33 (+1.35%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$24.35
$24.80
50-Day Range
$17.80
$25.65
52-Week Range
$12.24
$26.04
Volume
1.21 million shs
Average Volume
1.51 million shs
Market Capitalization
$4.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.43

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.47 Rating Score
Upside/​Downside
2.6% Upside
$25.43 Price Target
Short Interest
Bearish
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$5.31 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.56) to ($0.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

778th out of 1,010 stocks

Pharmaceutical Preparations Industry

390th out of 494 stocks


ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Down 6.1%
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
ACADIA Stock Gaps Down On Today's Open (ACAD)
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
H.C. Wainwright Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Citigroup Remains a Hold on ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals (ACAD) Gets a Buy from H.C. Wainwright
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
5/08/2023
Today
5/29/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.43
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
17 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-28.03%

Debt

Sales & Book Value

Annual Sales
$517.23 million
Book Value
$2.47 per share

Miscellaneous

Free Float
116,440,000
Market Cap
$4.03 billion
Optionable
Optionable
Beta
0.54

Key Executives

  • Stephen R. DavisStephen R. Davis
    Chief Executive Officer & Director
  • Brendan P. TeehanBrendan P. Teehan
    Chief Operating Officer, EVP & Head-Commercial
  • Mark C. Schneyer
    Chief Financial Officer & Executive Vice President
  • Ponni Subbiah
    Chief Medical Officer & Senior Vice President
  • Sanjeev Pathak
    Senior Vice President & Head-Clinical Development













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

17 brokerages have issued twelve-month target prices for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they expect the company's stock price to reach $25.43 in the next year. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 at the start of the year. Since then, ACAD stock has increased by 55.7% and is now trading at $24.78.
View the best growth stocks for 2023 here
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Monday, May, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.06. The biopharmaceutical company had revenue of $118.46 million for the quarter, compared to analysts' expectations of $120.29 million. ACADIA Pharmaceuticals had a negative net margin of 28.05% and a negative trailing twelve-month return on equity of 35.70%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.70) earnings per share.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $556.45 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (25.79%), BlackRock Inc. (6.08%), RTW Investments LP (5.07%), FMR LLC (4.84%), State Street Corp (3.44%) and Price T Rowe Associates Inc. MD (2.80%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $24.78.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $4.03 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -